Can immunotherapy specifically target acute myeloid leukemic stem cells?

Can immunotherapy specifically target acute myeloid leukemic stem cells?

Accumulating evidence supports the role of leukemic stem cells (LSCs) in the high relapse rate of acute myeloid leukemia (AML) patients. The clinical relevance of LSCs, which were originally characterized in xenograft models, has recently been confirmed by the finding that stem cell-like gene expres...

Full description

Bibliographic Details
Main Authors: Snauwaert, Sylvia, Vandekerckhove, Bart, Kerre, Tessa
Format: Online
Language:English
Published: Landes Bioscience 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601163/
id pubmed-3601163
recordtype oai_dc
spelling pubmed-36011632013-03-22 Can immunotherapy specifically target acute myeloid leukemic stem cells? Snauwaert, Sylvia Vandekerckhove, Bart Kerre, Tessa Review Accumulating evidence supports the role of leukemic stem cells (LSCs) in the high relapse rate of acute myeloid leukemia (AML) patients. The clinical relevance of LSCs, which were originally characterized in xenograft models, has recently been confirmed by the finding that stem cell-like gene expression signatures can predict the clinical outcome of AML patients. The targeted elimination of LSCs might hence constitute an efficient therapeutic approach to AML. Here, we review immunotherapeutic strategies that target LSC-associated antigens, including T cell-mediated and monoclonal antibody-based regimens. Attention is given to the issue of antigen specificity because this is relevant to the therapeutic window and determines the superiority of LSC-targeting immunotherapy. Landes Bioscience 2013-02-01 /pmc/articles/PMC3601163/ /pubmed/23526057 http://dx.doi.org/10.4161/onci.22943 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Snauwaert, Sylvia
Vandekerckhove, Bart
Kerre, Tessa
spellingShingle Snauwaert, Sylvia
Vandekerckhove, Bart
Kerre, Tessa
Can immunotherapy specifically target acute myeloid leukemic stem cells?
author_facet Snauwaert, Sylvia
Vandekerckhove, Bart
Kerre, Tessa
author_sort Snauwaert, Sylvia
title Can immunotherapy specifically target acute myeloid leukemic stem cells?
title_short Can immunotherapy specifically target acute myeloid leukemic stem cells?
title_full Can immunotherapy specifically target acute myeloid leukemic stem cells?
title_fullStr Can immunotherapy specifically target acute myeloid leukemic stem cells?
title_full_unstemmed Can immunotherapy specifically target acute myeloid leukemic stem cells?
title_sort can immunotherapy specifically target acute myeloid leukemic stem cells?
description Accumulating evidence supports the role of leukemic stem cells (LSCs) in the high relapse rate of acute myeloid leukemia (AML) patients. The clinical relevance of LSCs, which were originally characterized in xenograft models, has recently been confirmed by the finding that stem cell-like gene expression signatures can predict the clinical outcome of AML patients. The targeted elimination of LSCs might hence constitute an efficient therapeutic approach to AML. Here, we review immunotherapeutic strategies that target LSC-associated antigens, including T cell-mediated and monoclonal antibody-based regimens. Attention is given to the issue of antigen specificity because this is relevant to the therapeutic window and determines the superiority of LSC-targeting immunotherapy.
publisher Landes Bioscience
publishDate 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601163/
_version_ 1611963536887513088

Similar Items